Format

Send to

Choose Destination
Semin Cancer Biol. 2003 Dec;13(6):391-400.

Immunotherapy of melanoma.

Author information

1
Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G. Venezian, 1-20133 Milan, Italy. giorgio.parmiani@istitutotumori.mi.it

Abstract

The rationale for immunotherapy of human melanoma is based on the knowledge acquired in the molecular characterization of T cell defined antigens which are recognized in vitro by patients' lymphocytes. Based on this information, active immunotherapy (vaccination) and adoptive immunotherapy trials were conducted in metastatic melanoma patients. This review highlights the most important clinical studies and discuss their limits, in terms of both immune and clinical response considering the formulation of the vaccine (cellular, peptide/protein; DNA, etc.) or the features of immune cells used in adoptive immunotherapy. This new knowledge, along with that of escape mechanisms, should allow to improve significantly the clinical response rate in the immunotherapy of melanoma.

PMID:
15001157
DOI:
10.1016/j.semcancer.2003.09.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center